323 related articles for article (PubMed ID: 33026450)
1. Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer.
Lincoln SE; Nussbaum RL; Kurian AW; Nielsen SM; Das K; Michalski S; Yang S; Ngo N; Blanco A; Esplin ED
JAMA Netw Open; 2020 Oct; 3(10):e2019452. PubMed ID: 33026450
[TBL] [Abstract][Full Text] [Related]
2. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.
Mandelker D; Zhang L; Kemel Y; Stadler ZK; Joseph V; Zehir A; Pradhan N; Arnold A; Walsh MF; Li Y; Balakrishnan AR; Syed A; Prasad M; Nafa K; Carlo MI; Cadoo KA; Sheehan M; Fleischut MH; Salo-Mullen E; Trottier M; Lipkin SM; Lincoln A; Mukherjee S; Ravichandran V; Cambria R; Galle J; Abida W; Arcila ME; Benayed R; Shah R; Yu K; Bajorin DF; Coleman JA; Leach SD; Lowery MA; Garcia-Aguilar J; Kantoff PW; Sawyers CL; Dickler MN; Saltz L; Motzer RJ; O'Reilly EM; Scher HI; Baselga J; Klimstra DS; Solit DB; Hyman DM; Berger MF; Ladanyi M; Robson ME; Offit K
JAMA; 2017 Sep; 318(9):825-835. PubMed ID: 28873162
[TBL] [Abstract][Full Text] [Related]
3. Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.
Kurian AW; Ward KC; Hamilton AS; Deapen DM; Abrahamse P; Bondarenko I; Li Y; Hawley ST; Morrow M; Jagsi R; Katz SJ
JAMA Oncol; 2018 Aug; 4(8):1066-1072. PubMed ID: 29801090
[TBL] [Abstract][Full Text] [Related]
4. Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer.
Berchuck JE; Boiarsky D; Silver R; Sunkara R; McClure HM; Tsai HK; Siegmund S; Tewari AK; Nowak JA; Lindeman NI; Rana HQ; Choudhury AD; Pomerantz MM; Freedman ML; Van Allen EM; Taplin ME
JCO Precis Oncol; 2022 Aug; 6():e2200329. PubMed ID: 36103646
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines.
Yap TA; Ashok A; Stoll J; Mauer E; Nepomuceno VM; Blackwell KL; Garber JE; Meric-Bernstam F
JAMA Netw Open; 2022 May; 5(5):e2213070. PubMed ID: 35594047
[TBL] [Abstract][Full Text] [Related]
6. Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA.
Schrader KA; Cheng DT; Joseph V; Prasad M; Walsh M; Zehir A; Ni A; Thomas T; Benayed R; Ashraf A; Lincoln A; Arcila M; Stadler Z; Solit D; Hyman DM; Zhang L; Klimstra D; Ladanyi M; Offit K; Berger M; Robson M
JAMA Oncol; 2016 Jan; 2(1):104-11. PubMed ID: 26556299
[TBL] [Abstract][Full Text] [Related]
7. Germline Testing Data Validate Inferences of Mutational Status for Variants Detected From Tumor-Only Sequencing.
Jalloul N; Gomy I; Stokes S; Gusev A; Johnson BE; Lindeman NI; Macconaill L; Ganesan S; Garber JE; Khiabanian H
JCO Precis Oncol; 2021; 5():. PubMed ID: 34820595
[TBL] [Abstract][Full Text] [Related]
8. Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer.
Whitworth PW; Beitsch PD; Patel R; Rosen B; Compagnoni G; Baron PL; Simmons R; Brown EA; Gold L; Holmes D; Smith LA; Kinney M; Grady I; Clark P; Barbosa K; Lyons S; Riley L; Coomer C; Curcio L; Ruiz A; Khan S; MacDonald H; Hughes K; Hardwick MK; Heald B; Munro SB; Nielsen SM; Esplin ED
JAMA Netw Open; 2022 Sep; 5(9):e2232787. PubMed ID: 36136330
[TBL] [Abstract][Full Text] [Related]
9. Germline Genetic Testing in Unselected Squamous and Non-Squamous Head and Neck Cancers.
Brake DA; Idler BM; Kunze KL; Golafshar MA; Heald B; Young S; Klint M; Barrus K; Esplin ED; Nussbaum RL; Samadder NJ; Hinni ML; Chang BA
Laryngoscope; 2023 Dec; 133(12):3378-3388. PubMed ID: 37132629
[TBL] [Abstract][Full Text] [Related]
10. Feasibility and Clinical Utility of Reporting Hereditary Cancer Predisposition Pathogenic Variants Identified in Research Germline Sequencing: A Prospective Interventional Study.
Hutchcraft ML; Zhang S; Lin N; Pickarski JC; Belcher EA; Wei S; Bocklage T; Miller RW; Villano JL; Cavnar MJ; Kim J; Arnold SM; Ueland FR; Kolesar JM
JCO Precis Oncol; 2024 Jan; 8():e2300266. PubMed ID: 38295319
[TBL] [Abstract][Full Text] [Related]
11. Half of germline pathogenic and likely pathogenic variants found on panel tests do not fulfil NHS testing criteria.
Andoni T; Wiggins J; Robinson R; Charlton R; Sandberg M; Eeles R
Sci Rep; 2022 Feb; 12(1):2507. PubMed ID: 35190596
[TBL] [Abstract][Full Text] [Related]
12. Pathogenic Germline Variants in BRCA1/2 and p53 Identified by Real-world Comprehensive Cancer Genome Profiling Tests in Asian Patients.
Satake T; Kondo S; Tanabe N; Mizuno T; Katsuya Y; Sato J; Koyama T; Yoshida T; Hirata M; Yamamoto N
Cancer Res Commun; 2023 Nov; 3(11):2302-2311. PubMed ID: 37916805
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and spectrum of cancer predisposition germline mutations in young patients with the common late-onset cancers.
Hao S; Zhao X; Fan Y; Liu Z; Zhang X; Li W; Yuan H; Zhang J; Zhang Y; Ma T; Tao H
Cancer Med; 2023 Sep; 12(17):18394-18404. PubMed ID: 37610374
[TBL] [Abstract][Full Text] [Related]
14. Unexpected actionable genetic variants revealed by multigene panel testing of patients with uterine cancer.
Heald B; Mokhtary S; Nielsen SM; Rojahn S; Yang S; Michalski ST; Esplin ED
Gynecol Oncol; 2022 Aug; 166(2):344-350. PubMed ID: 35691755
[TBL] [Abstract][Full Text] [Related]
15. Molecular characteristics of breast tumors in patients screened for germline predisposition from a population-based observational study.
Nacer DF; Vallon-Christersson J; Nordborg N; Ehrencrona H; Kvist A; Borg Å; Staaf J
Genome Med; 2023 Apr; 15(1):25. PubMed ID: 37060015
[TBL] [Abstract][Full Text] [Related]
16. The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials.
McVeigh TP; Sundar R; Diamantis N; Kaye SB; Banerji U; Lopez JS; de Bono J; van der Graaf WTA; George AJ
Eur J Cancer; 2018 May; 95():20-29. PubMed ID: 29614442
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing.
Terraf P; Pareja F; Brown DN; Ceyhan-Birsoy O; Misyura M; Rana S; O'Reilly E; Carlo MI; Aghajanian C; Liu Y; Derakhshan F; Jayakumaran G; Weigelt B; Walsh M; Stadler Z; Offit K; Ladanyi M; Robson M; Zehir A; Reis-Filho JS; Mandelker D
Ann Oncol; 2022 Apr; 33(4):426-433. PubMed ID: 35074424
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome.
Samadder NJ; Riegert-Johnson D; Boardman L; Rhodes D; Wick M; Okuno S; Kunze KL; Golafshar M; Uson PLS; Mountjoy L; Ertz-Archambault N; Patel N; Rodriguez EA; Lizaola-Mayo B; Lehrer M; Thorpe CS; Yu NY; Esplin ED; Nussbaum RL; Sharp RR; Azevedo C; Klint M; Hager M; Macklin-Mantia S; Bryce AH; Bekaii-Saab TS; Sekulic A; Stewart AK
JAMA Oncol; 2021 Feb; 7(2):230-237. PubMed ID: 33126242
[TBL] [Abstract][Full Text] [Related]
19. Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry.
Yurgelun MB; Masciari S; Joshi VA; Mercado RC; Lindor NM; Gallinger S; Hopper JL; Jenkins MA; Buchanan DD; Newcomb PA; Potter JD; Haile RW; Kucherlapati R; Syngal S;
JAMA Oncol; 2015 May; 1(2):214-21. PubMed ID: 26086041
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.
Hampel H; Pearlman R; Beightol M; Zhao W; Jones D; Frankel WL; Goodfellow PJ; Yilmaz A; Miller K; Bacher J; Jacobson A; Paskett E; Shields PG; Goldberg RM; de la Chapelle A; Shirts BH; Pritchard CC;
JAMA Oncol; 2018 Jun; 4(6):806-813. PubMed ID: 29596542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
